Initiate dosing in pediatric PK run-in study for adolescents
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Dec 2024
- Due
- 31 Mar 2025
- Delivered
- January 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Screening of adolescents with FA is ongoing for the pediatric PK run-in study with dosing expected early 2025”
What we found
Evidence strength A What the grades mean
The company successfully initiated dosing in the adolescent PK run-in study in January 2025, which is within the early 2025 timeframe.
-
A Larimar Therapeutics, Inc. 10-Q filed 2025-04-30
“In January 2025, the Company initiated dosing of adolescents (12-17 years old) in a pharmacokinetic ("PK") run-in study for pediatric patients with FA.” ✓ confirmed on the page
Market reaction: the shares moved +22.0% against the S&P 500 over the three sessions around the disclosure (29 Apr 2025 to 2 May 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Pediatric PK run-in study dosing
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-003016 · Corrections policy